The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
about
Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe.Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia.Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
P2860
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@ast
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@en
type
label
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@ast
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@en
prefLabel
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@ast
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@en
P2093
P2860
P50
P356
P1433
P1476
The BET bromodomain inhibitor ...... ds and anti-microtubule drugs.
@en
P2093
Andrew E Tee
Belamy B Cheung
Bernard Atmadibrata
Faraz Siddiqi
Glenn M Marshall
Jenny Wang
Joshua Mccarroll
P2860
P304
79217-79232
P356
10.18632/ONCOTARGET.12640
P407
P577
2016-10-13T00:00:00Z